Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
47.99
-0.97 (-1.98%)
Nov 21, 2024, 11:53 AM EST - Market open
Janux Therapeutics Revenue
Janux Therapeutics had revenue of $439.00K in the quarter ending September 30, 2024, a decrease of -82.56%. This brings the company's revenue in the last twelve months to $13.05M, up 54.12% year-over-year. In the year 2023, Janux Therapeutics had annual revenue of $8.08M, down -6.14%.
Revenue (ttm)
$13.05M
Revenue Growth
+54.12%
P/S Ratio
192.16
Revenue / Employee
$203,891
Employees
64
Market Cap
2.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.08M | -529.00K | -6.14% |
Dec 31, 2022 | 8.61M | 4.98M | 136.79% |
Dec 31, 2021 | 3.64M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Ardent Health Partners | 5.71B |
QuidelOrtho | 2.82B |
Amneal Pharmaceuticals | 2.68B |
Privia Health Group | 1.72B |
Catalyst Pharmaceuticals | 460.48M |
Twist Bioscience | 312.97M |
Iovance Biotherapeutics | 90.86M |
JANX News
- 2 days ago - Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation - Seeking Alpha
- 14 days ago - Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Business Wire
- 3 months ago - Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Business Wire
- 4 months ago - Janux Therapeutics Announces Updates to Board of Directors - Business Wire
- 5 months ago - Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy - Seeking Alpha
- 7 months ago - Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire
- 7 months ago - Janux Therapeutics (JANX) stock has gone parabolic: what next? - Invezz
- 8 months ago - Janux Therapeutics: A Prime Target In Cancer Care's M&A Game - Seeking Alpha